BRCA1 and breast carcinoma: Our previous research profiled plasma levels of some resolvins in breast cancer patients and identified significant associations with the type of disease presentation, genetic signature (BRCA1/2 mutation), and immunohistochemical characteristics, including the triple-negative phenotype and high Ki67 expression [18].